Provided by Tiger Trade Technology Pte. Ltd.

Johnson & Johnson

267.20
+0.88000.33%
Post-market: 265.00-2.2000-0.82%19:59 EDT
Volume:5.28M
Turnover:1.40B
Market Cap:643.76B
PE:30.94
High:267.20
Open:265.81
Low:260.68
Close:266.32
52wk High:281.07
52wk Low:173.33
Shares:2.41B
Float Shares:2.40B
Volume Ratio:0.92
T/O Rate:0.22%
Dividend:5.24
Dividend Rate:1.96%
EPS(TTM):8.64
EPS(LYR):11.03
ROE:25.74%
ROA:8.59%
PB:7.58
PE(LYR):24.22

Loading ...

Estee Lauder Cos. Cl a Stock Underperforms Tuesday When Compared to Competitors

Dow Jones
·
8 hours ago

Health Rounds: New Dye for MRI Exams Detects Lung Cancer Earlier

Reuters
·
10 hours ago

As Trump Backs Psychedelics Research, FDA Weighs Safety and Access Standards

Reuters
·
Yesterday

LIVE Markets-Autumn in New York: Factory Expansion Slows, Input Prices at Multi-Year Highs - Empire State

Reuters
·
Yesterday

LIVE Markets-US Stock Indexes Swing Lower as Oil, Yields Jump

Reuters
·
Yesterday

Dow's Nearly 300-Point Fall Led by Losses in Johnson & Johnson, Nike Stocks

Dow Jones
·
Yesterday

Johnson & Johnson Says Subcutaneous Cancer Treatment Study Shows Low Rates Across Key Events, Discontinuation

MT Newswires Live
·
Yesterday

JNJ Reports Low Rates of Treatment-Related Events for Rybrevant Faspro Plus Lazcluze at Wclc 2026

Reuters
·
Yesterday

J&J - Fewer than 1% Discontinue Rybrevant Faspro Plus Lazcluze Due to Treatment-Related Events at One Year

THOMSON REUTERS
·
Yesterday

Contineum Therapeutics Says Phase 2 Major Depressive Disorder Study Fails to Meet Primary Efficacy Endpoint

MT Newswires Live
·
Yesterday

Medtronic PLC Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Yesterday

Contineum Therapeutics Shares Fall After Drug Trial Missed Primary Endpoint

Dow Jones
·
Yesterday

Contineum, J&J's Depression Drug Fails to Meet Mid-Stage Trial Goal

Reuters
·
Yesterday

Contineum Therapeutics, - Johnson & Johnson Continues to Evaluate Trial Data for Jnj-5120/Pipe-307

THOMSON REUTERS
·
Yesterday

Sector Update: Healthcare Stocks Rise Premarket Monday

MT Newswires Live
·
Sep 14

U.S. Stocks on the MOVE-US Energy Stocks, Baldwin, Johnson & Johnson

Reuters
·
Sep 14

J&J - Jnj Reports Rybrevant Plus Chemotherapy Extends Pfs2 by 10.8 Months in Nsclc

THOMSON REUTERS
·
Sep 14

Johnson & Johnson’s Rybrevant® (Amivantamab-Vmjw) Plus Chemotherapy Delivers Longest Reported Median Overall Survival in Egfr Exon 20 Insertion Mutation-Positive Lung Cancer

THOMSON REUTERS
·
Sep 14

J&J - Jnj Reports no New Safety Signals for Rybrevant Plus Chemotherapy in Nsclc Study

THOMSON REUTERS
·
Sep 14

Potential Buyer Emerges for Johnson & Johnson's Orthopedics Unit

Deep News
·
Sep 14